Apr 18, 2024 7:30am EDT Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Apr 18, 2024 7:00am EDT Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
Apr 18, 2024 9:00 am EDT – 11:00 am EDT Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy